axovant sciences ltd logo

Axovant Sciences, Inc.

Axovant Sciences is dedicated to delivering novel therapeutic solutions to patients living with dementia today Axovant Sciences, AXON (NYSE) a majority-owned subsidiary of Roivant, is a clinical-stage biopharmaceutical company dedicated to comprehensively addressing the cognitive, behavioral, and functional components of dementia.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”AXON” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://axovant.com
Founded2015
Disease Focus
Development Stage
STOCK CODENASDAQ: AXON
Address
11 Times Square 33rd Floor, NY 10036
New York
United States
Email
Contact Number
+1 833 296 8268

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/axovant” connections=”true” suffix=””]

July 2018, Axovant licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal muscular dystrophy. Axovant will pay Benitec an upfront payment of $10 million for rights to the AXO-AAV-OPMD program and five additional investigational gene therapy products, as well as payments tied to development, regulatory and commercial sales milestones.

In June 2018, Axovant licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from Oxford BioMedica an investigational gene therapy for Parkinsons disease as well as its predecessor product ProSavinë.

In Nov 2015, Axovant Sciences Ltd. received an option to acquired exclusive, worldwide to develop and commercialize nelotanserin from Axovants majority owner, Roivant Sciences Ltd.

In Jun 2015, Axovant Sciences raised approx. $360 Mn USD through IPO listing to fund Phase III clinical studies of RVT-101.